News

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO). Since March of 2014 Nascent has raised $2.1 million which has been used to advance the [...]

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its [...]

San Diego, CA, June 4th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) Nascent Biotech, Inc announced that it has begun toxicology trials on its primary asset Pritumumab, a monoclonal antibody [...]

San Diego, CA, April 9th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the [...]

San Diego, CA, February 26th, 2015 – Nascent Biotech, Inc. (OTC: NBIO) and Mapp Biopharmaceutical announced today they have been awarded a $225,000 Small Business Innovative Research (SBIR) [...]

San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million. Management raised [...]

Nascent Biotech will be a key sponsor of the 2015 edition of the Human Antibodies & Hybridomas Conference, held October 28-30, 2015, at the University of Lausanne/CHUV, in Lausanne, [...]

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta authored a new paper published in the Handbook of Therapeutic Antibodies, Second [...]

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta have contributed a chapter to Humana Press’ new book “Human Monoclonal [...]

Please click to download the 2014 Cancer Facts and Figures PDF released by the American Cancer Society. In addition, please review this document, entitled “Cancer Statistics, 2011; The [...]